HIV clinicians will need a basic understanding of the most important characteristics of low-level resistant variants as they pertain to their impact on therapy in order to best utilize these new ...
Throughout modern medical history, Americans have underestimated or dismissed emerging health threats until the consequences ...
The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...
GlobalData on MSN6d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
The new vaccines, directed against the KP family, are from Pfizer and Moderna. The vaccinations are interchangeable and ...
Sensitive genotyping methods have been an invaluable investigative tool to determine the impact of low-level resistant variants on treatment outcome. It is imperative for the proper diagnosis and ...
ThePrint on MSN4d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
Daily Maverick on MSN5d
Glenda Gray's fierce fight for science, the Covid-19 ruckus, and the bathroom row about HIV drugsProfessor Glenda Gray, the first woman president and chief executive of the SA Medical Research Council has been described as ...
Earlier this month, the ongoing BEEHIVE (Bridging the Epidemiology and Evolution of HIV in Europe) project reported their detection of the new variant of subtype-B HIV-1, the most common type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback